Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.88 USD

2.88
5,883,771

+0.38 (15.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.93 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice

Does ImmunoGen (IMGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

ImmunoGen (IMGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for ImmunoGen (IMGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

New Strong Buy Stocks for November 29th

TM, PAY, WRB, MNDY and IMGN have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2023.

Wall Street Analysts Believe ImmunoGen (IMGN) Could Rally 52.99%: Here's is How to Trade

The mean of analysts' price targets for ImmunoGen (IMGN) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

New Strong Buy Stocks for November 22nd

RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.

Best Momentum Stocks to Buy for November 16th

IMGN, MDV and VECO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 16:

New Strong Buy Stocks for November 16th

IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.

ImmunoGen (IMGN) Just Overtook the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

ImmunoGen (IMGN) Crossed Above the 50-Day Moving Average: What That Means for Investors

When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

Best Momentum Stocks to Buy for November 8th

APPF, IMGN and COIN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2023.

Zacks.com featured highlights include Confluent, Pinterest, ICON and ImmunoGen

Confluent, Pinterest, ICON and ImmunoGen are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

4 Stocks to Invest in for Remarkable Earnings Acceleration

Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.

Wall Street Analysts See a 40.58% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?

The consensus price target hints at a 40.6% upside potential for ImmunoGen (IMGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.

ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 400% and 6.02%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?

ImmunoGen (IMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen

Fresenius Medical Care, Vericel and ImmunoGen are part of the Zacks Investment Ideas article.

Shaun Pruitt headshot

Top Medical Stocks to Buy Amid Recent Market Volatility

Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.